Travere Therapeutics
TVTX
130 hedge funds and large institutions have $934M invested in Travere Therapeutics in 2018 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 21 closing their positions.
83% more call options, than puts
Call options by funds: $9.46M | Put options by funds: $5.17M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
2% more funds holding
Funds holding: 128 → 130 (+2)
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
5% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 44
2.72% less ownership
Funds ownership: 105.56% → 102.83% (-2.7%)
23% less capital invested
Capital invested by funds: $1.21B → $934M (-$273M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$16.2M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$8.45M |
| 3 |
Two Sigma Investments
New York
|
+$5.33M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.54M |
| 5 |
Handelsbanken Fonder
Stockholm,
Sweden
|
+$4.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$20.4M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$15.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$12.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.17M |
| 5 |
Millennium Management
New York
|
-$5.68M |
TVTX Hedge Fund Activity: Q4 2018 in Review
130 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2018, worth a combined $934M — down 23% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TVTX positions and 21 closed out — a net gain of 2 holders — while 46 added to existing stakes and 44 trimmed.
The largest buyer was Bank of America, adding an estimated $16.2M. The largest seller was Deutsche Bank, cutting an estimated $20.4M.
- 130 institutional investors held Travere Therapeutics (TVTX) as of Q4 2018, up from 128 in Q3 2018.
- Funds reported $934M of Travere Therapeutics stock for Q4 2018, down 23% quarter-over-quarter.
- 23 funds opened new Travere Therapeutics positions in Q4 2018 and 21 closed out, a net change of +2 holders.
- The largest Travere Therapeutics buyer in Q4 2018 was Bank of America, an estimated $16.2M added.
- The largest Travere Therapeutics seller in Q4 2018 was Deutsche Bank, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2018.